Inclusion Criteria
A patient will be eligible for inclusion in this study if all of the following criteria apply:
- Uveal or cutaneous melanoma with MRD detected in molecular screening.
- Written (signed and dated) informed consent and be capable of co-operating with protocol
- Male or female, Age ³ 18 years.
- Life expectancy of at least 3 months.
- ECOG performance score of 0 or 1.
- No evidence of metastatic disease on a CT scan of neck/thorax/abdomen/pelvis for cohorts A and B and also on MRI liver for uveal melanoma for cohort B.
- Those receiving prior immunotherapy must have recovered from any immune-mediated adverse events (≤ grade 1) other than endocrinopathies on stable replacement therapy.
- Haematological and biochemical indices within the ranges shown in the trial protocol.
